期刊
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
卷 21, 期 4, 页码 771-775出版社
BMJ PUBLISHING GROUP
DOI: 10.1097/IGC.0b013e31821bb8aa
关键词
Ovarian cancer; Recurrent; Clinical trials
资金
- Astra Zeneca
- Roche
- GlaxoSmithKline
- Pharmamar
- Ortho Biotech
- Boehringer Ingelheim
- Canadian Cancer Society Research Institute
- Ovarian Cancer Canada
- National Cancer Institute (US)
- Taiho
- Merck
- Pfizer
- Amgen
The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. Group C, 1 of the 3 discussion groups, examined recurrent ovarian cancer, and we report the consensus reached regarding 4 questions. These included the following: (1) What is the role of cytoreductive surgery for recurrent ovarian cancer? (2) How do we define distinct patient populations in need of specific therapeutic approaches? (3) Should end points for trials with recurrent disease vary from those of first-line trials? (4) Is CA-125 progression alone sufficient for entry/eligibility into clinical trials?
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据